Bibliography: library/10665-354214
The reference for library/10665-354214 (who-iris) and any references extracted from it. library · All references.
Export these 20 references: BibTeX · CSL-JSON · RIS · Dublin Core XML · Dublin Core / BIBO JSON-LD
✍ + Add reference (standalone node)
20 shown
-
Всемирная организация здравоохранения (2022). Предварительные рекомендации по применению инактивированной вакцины CoronaVac против COVID-19, разработанной Sinovac: Временное руководство (Первый выпуск 24 мая 2021 г., Обновлено 21 октября 2021 г., Обновлено 15 марта 2022 г.). Всемирная организация здравоохранения. Европейское региональное бюро.
10665-354214· catalogue · link · repository record · source:catalogue/records/10665-354214.dc.json· held:library/10665-354214
export: BibTeX · RIS · CSL-JSON · DC XML -
Guidance for the development of evidence-based vaccination-related recommendations. Geneva: World Health Organization; 2017. (https://www.who.int/immunization/sage/Guidelines_development_recommendations.pdf, доступо 15 марта 2022 г.).
· extracted · link · source:references/10665-354214.sec-004.1.jsonGuidance for the development of evidence-based vaccination-related recommendations. Geneva: World Health Organization; 2017. (https://www.who.int/immunization/sage/Guidelines_development_recommendations.pdf, доступо 15 марта 2022 г.).
- Issued
- 2022
- Type
- document
- As printed
- Guidance for the development of evidence-based vaccination-related recommendations. Geneva: World Health Organization; 2017. (https://www.who.int/immunization/sage/Guidelines_development_recommendations.pdf, доступо 15 марта 2022 г.).
Sources
In the knowledge graph
- IRI
references/10665-354214.sec-004.1 - provenance: extracted
- read from
references/10665-354214.sec-004.1.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-354214/sections/sec-004-список-литературы.md
-
Evidence to recommendations for COVID-19 vaccines: evidence framework. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/handle/10665/337569, доступо 15 марта 2022 г.).
· extracted · link · source:references/10665-354214.sec-004.2.jsonEvidence to recommendations for COVID-19 vaccines: evidence framework. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/handle/10665/337569, доступо 15 марта 2022 г.).
- Issued
- 2022
- Type
- document
- As printed
- Evidence to recommendations for COVID-19 vaccines: evidence framework. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/handle/10665/337569, доступо 15 марта 2022 г.).
Sources
- apps.who.int/iris/handle/10665/337569 (canonical)
In the knowledge graph
- IRI
references/10665-354214.sec-004.2 - provenance: extracted
- read from
references/10665-354214.sec-004.2.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-354214/sections/sec-004-список-литературы.md
-
WHO SAGE roadmap for prioritizing uses of COVID-19 vaccines. Geneva: World Health Organization (https://www.who.int/publications/i/item/WHO-2019-nCoV-Vaccines-SAGE-Prioritization-2022.1, доступо 20 января 2022 г.).
· extracted · link · source:references/10665-354214.sec-004.3.jsonWHO SAGE roadmap for prioritizing uses of COVID-19 vaccines. Geneva: World Health Organization (https://www.who.int/publications/i/item/WHO-2019-nCoV-Vaccines-SAGE-Prioritization-2022.1, доступо 20 января 2022 г.).
- Issued
- 2022
- Type
- document
- As printed
- WHO SAGE roadmap for prioritizing uses of COVID-19 vaccines. Geneva: World Health Organization (https://www.who.int/publications/i/item/WHO-2019-nCoV-Vaccines-SAGE-Prioritization-2022.1, доступо 20 января 2022 г.).
Sources
In the knowledge graph
- IRI
references/10665-354214.sec-004.3 - provenance: extracted
- read from
references/10665-354214.sec-004.3.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-354214/sections/sec-004-список-литературы.md
-
WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination. Geneva: World Health Organization; 2020 (www.who.int/publications/i/item/who-sage-values-framework-for-the-allocation-and-prioritization-of-covid-19-vaccination, доступно 15 марта 2022 г.).
· extracted · link · source:references/10665-354214.sec-004.4.jsonWHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination. Geneva: World Health Organization; 2020 (www.who.int/publications/i/item/who-sage-values-framework-for-the-allocation-and-prioritization-of-covid-19-vaccination, доступно 15 марта 2022 г.).
- Issued
- 2022
- Type
- document
- As printed
- WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination. Geneva: World Health Organization; 2020 (www.who.int/publications/i/item/who-sage-values-framework-for-the-allocation-and-prioritization-of-covid-19-vaccination, доступно 15 марта 2022 г.).
Sources
In the knowledge graph
- IRI
references/10665-354214.sec-004.4 - provenance: extracted
- read from
references/10665-354214.sec-004.4.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-354214/sections/sec-004-список-литературы.md
-
Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19: background document to the WHO Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac, 24 May 2021. Geneva: World Health Organization 2021. (https://apps.who.int/iris/handle/10665/341455, доступно 15 марта 2022 г.).
· extracted · link · source:references/10665-354214.sec-004.5.jsonBackground document on the inactivated vaccine Sinovac-CoronaVac against COVID-19: background document to the WHO Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac, 24 May 2021. Geneva: World Health Organization 2021. (https://apps.who.int/iris/handle/10665/341455, доступно 15 марта 2022 г.).
- Issued
- 2022
- Type
- document
- As printed
- Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19: background document to the WHO Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac, 24 May 2021. Geneva: World Health Organization 2021. (https://apps.who.int/iris/handle/10665/341455, доступно 15 марта 2022 г.).
Sources
- apps.who.int/iris/handle/10665/341455 (canonical)
In the knowledge graph
- IRI
references/10665-354214.sec-004.5 - provenance: extracted
- read from
references/10665-354214.sec-004.5.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-354214/sections/sec-004-список-литературы.md
-
Jara A, Undurraga EA, Gonzalez C, Paredes F, Fontecilla T, Jara G et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med. 2021;385:875-84. doi: 10.1056/NEJMoa2107715.
· extracted · doi:10.1056/NEJMoa2107715 · source:references/10665-354214.sec-004.6.jsonJara A, Undurraga EA, Gonzalez C, Paredes F, Fontecilla T, Jara G et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med. 2021;385:875-84. doi: 10.1056/NEJMoa2107715.
- Issued
- 2021
- Type
- article-journal
- DOI
- 10.1056/NEJMoa2107715
- As printed
- Jara A, Undurraga EA, Gonzalez C, Paredes F, Fontecilla T, Jara G et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med. 2021;385:875-84. doi: 10.1056/NEJMoa2107715.
Sources
In the knowledge graph
- IRI
references/10665-354214.sec-004.6 - provenance: extracted
- read from
references/10665-354214.sec-004.6.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-354214/sections/sec-004-список-литературы.md
-
Li M, Yang J, Wang L, Wu Q, Wu Z, Zheng W et al. A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. medRxiv. 2021:2021.08.03.21261544. doi: 10.1101/2021.08.03.21261544.
· extracted · doi:10.1101/2021.08.03.21261544 · source:references/10665-354214.sec-004.7.jsonLi M, Yang J, Wang L, Wu Q, Wu Z, Zheng W et al. A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. medRxiv. 2021:2021.08.03.21261544. doi: 10.1101/2021.08.03.21261544.
- Issued
- 2021
- Type
- document
- DOI
- 10.1101/2021.08.03.21261544
- As printed
- Li M, Yang J, Wang L, Wu Q, Wu Z, Zheng W et al. A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. medRxiv. 2021:2021.08.03.21261544. doi: 10.1101/2021.08.03.21261544.
Sources
In the knowledge graph
- IRI
references/10665-354214.sec-004.7 - provenance: extracted
- read from
references/10665-354214.sec-004.7.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-354214/sections/sec-004-список-литературы.md
-
Pan H, Wu Q, Zeng G, Yang J, Jiang D, Deng X et al. Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial. medRxiv. 2021:2021.07.23.21261026. doi: 10.1101/2021.07.23.21261026.
· extracted · doi:10.1101/2021.07.23.21261026 · source:references/10665-354214.sec-004.8.jsonPan H, Wu Q, Zeng G, Yang J, Jiang D, Deng X et al. Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial. medRxiv. 2021:2021.07.23.21261026. doi: 10.1101/2021.07.23.21261026.
- Issued
- 2021
- Type
- document
- DOI
- 10.1101/2021.07.23.21261026
- As printed
- Pan H, Wu Q, Zeng G, Yang J, Jiang D, Deng X et al. Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial. medRxiv. 2021:2021.07.23.21261026. doi: 10.1101/2021.07.23.21261026.
Sources
In the knowledge graph
- IRI
references/10665-354214.sec-004.8 - provenance: extracted
- read from
references/10665-354214.sec-004.8.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-354214/sections/sec-004-список-литературы.md
-
Costa Clemens SA, Weckx L, Clemens R, Almeida Mendes AV, Ramos Souza A, Silveira MBV et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. The Lancet. 2022;399:521-9. doi:
· extracted · source:references/10665-354214.sec-004.9.jsonCosta Clemens SA, Weckx L, Clemens R, Almeida Mendes AV, Ramos Souza A, Silveira MBV et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. The Lancet. 2022;399:521-9. doi:
- Issued
- 2022
- Type
- article-journal
- As printed
- Costa Clemens SA, Weckx L, Clemens R, Almeida Mendes AV, Ramos Souza A, Silveira MBV et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. The Lancet. 2022;399:521-9. doi:
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-354214.sec-004.9 - provenance: extracted
- read from
references/10665-354214.sec-004.9.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-354214/sections/sec-004-список-литературы.md
-
1016/S0140-6736(22)00094-0. 10. Jara, Alejandro and Undurraga, Eduardo A. and Zubizarreta, José R. and Gonzalez, Cecilia and Pizarro, Alejandra and Acevedo, Johanna and Leo, Katherinne and Paredes, Fabio and Bralic, Tomas and Vergara, Veronica and Mosso, Marcelo and Leon, Francisco and Parot, Ignacio and Leighton, Paulina and Suarez, Pamela and Rios, Juan Carlos and García-Escorza, Heriberto and Araos, Rafael, Effectiveness of Homologous and Heterologous Booster Shots for an Inactivated SARS-CoV-2 Vaccine: A Large-Scale Observational Study. Available at SSRN: https://ssrn.com/abstract=4005130 or http://dx.doi.org/10.2139/ssrn.4005130.
· extracted · link · doi:10.2139/ssrn.4005130 · source:references/10665-354214.sec-004.10.json1016/S0140-6736(22)00094-0. 10. Jara, Alejandro and Undurraga, Eduardo A. and Zubizarreta, José R. and Gonzalez, Cecilia and Pizarro, Alejandra and Acevedo, Johanna and Leo, Katherinne and Paredes, Fabio and Bralic, Tomas and Vergara, Veronica and Mosso, Marcelo and Leon, Francisco and Parot, Ignacio and Leighton, Paulina and Suarez, Pamela and Rios, Juan Carlos and García-Escorza, Heriberto and Araos, Rafael, Effectiveness of Homologous and Heterologous Booster Shots for an Inactivated SARS-CoV-2 Vaccine: A Large-Scale Observational Study. Available at SSRN: https://ssrn.com/abstract=4005130 or http://dx.doi.org/10.2139/ssrn.4005130.
- Type
- document
- DOI
- 10.2139/ssrn.4005130
- As printed
- 1016/S0140-6736(22)00094-0. 10. Jara, Alejandro and Undurraga, Eduardo A. and Zubizarreta, José R. and Gonzalez, Cecilia and Pizarro, Alejandra and Acevedo, Johanna and Leo, Katherinne and Paredes, Fabio and Bralic, Tomas and Vergara, Veronica and Mosso, Marcelo and Leon, Francisco and Parot, Ignacio and Leighton, Paulina and Suarez, Pamela and Rios, Juan Carlos and García-Escorza, Heriberto and Araos, Rafael, Effectiveness of Homologous and Heterologous Booster Shots for an Inactivated SARS-CoV-2 Vaccine: A Large-Scale Observational Study. Available at SSRN: https://ssrn.com/abstract=4005130 or http://dx.doi.org/10.2139/ssrn.4005130.
Sources
- ssrn.com/abstract=4005130 (canonical)
- doi:10.2139/ssrn.4005130 (doi)
In the knowledge graph
- IRI
references/10665-354214.sec-004.10 - provenance: extracted
- read from
references/10665-354214.sec-004.10.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-354214/sections/sec-004-список-литературы.md
-
Interim recommendations for heterologous COVID-19 vaccine schedules. Geneva: World Health Organization 2021 (https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-heterologous-schedules, доступно 16 декабря 2021 г.).
· extracted · link · source:references/10665-354214.sec-004.11.jsonInterim recommendations for heterologous COVID-19 vaccine schedules. Geneva: World Health Organization 2021 (https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-heterologous-schedules, доступно 16 декабря 2021 г.).
- Issued
- 2021
- Type
- document
- As printed
- Interim recommendations for heterologous COVID-19 vaccine schedules. Geneva: World Health Organization 2021 (https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-heterologous-schedules, доступно 16 декабря 2021 г.).
Sources
- www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-heterologous-schedules (canonical)
In the knowledge graph
- IRI
references/10665-354214.sec-004.11 - provenance: extracted
- read from
references/10665-354214.sec-004.11.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-354214/sections/sec-004-список-литературы.md
-
Izikson R, Brune D, Bolduc J, Bourron P, Fournier M, Moore T et al. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults ≥ 65 years of age: a Phase II, open-label study. 2021. doi: doi: https://doi.org/10.1101/2021.10.29.21265248.
· extracted · doi:10.1101/2021.10.29.21265248 · source:references/10665-354214.sec-004.12.jsonIzikson R, Brune D, Bolduc J, Bourron P, Fournier M, Moore T et al. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults ≥ 65 years of age: a Phase II, open-label study. 2021. doi: doi: https://doi.org/10.1101/2021.10.29.21265248.
- Issued
- 2021
- Type
- document
- DOI
- 10.1101/2021.10.29.21265248
- As printed
- Izikson R, Brune D, Bolduc J, Bourron P, Fournier M, Moore T et al. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults ≥ 65 years of age: a Phase II, open-label study. 2021. doi: doi: https://doi.org/10.1101/2021.10.29.21265248.
Sources
In the knowledge graph
- IRI
references/10665-354214.sec-004.12 - provenance: extracted
- read from
references/10665-354214.sec-004.12.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-354214/sections/sec-004-список-литературы.md
-
WHO SAGE roadmap for prioritizing uses of COVID-19 vaccines in the context of limited supply. Geneva: World Health Organization 2020 (https://www.who.int/publications/i/item/who-sage-roadmap-for-prioritizing-uses-of-covid-19-vaccines-in-the-context-of-limited-supply, доступно 4 июня 2021 г.).
· extracted · link · source:references/10665-354214.sec-004.13.jsonWHO SAGE roadmap for prioritizing uses of COVID-19 vaccines in the context of limited supply. Geneva: World Health Organization 2020 (https://www.who.int/publications/i/item/who-sage-roadmap-for-prioritizing-uses-of-covid-19-vaccines-in-the-context-of-limited-supply, доступно 4 июня 2021 г.).
- Issued
- 2021
- Type
- document
- As printed
- WHO SAGE roadmap for prioritizing uses of COVID-19 vaccines in the context of limited supply. Geneva: World Health Organization 2020 (https://www.who.int/publications/i/item/who-sage-roadmap-for-prioritizing-uses-of-covid-19-vaccines-in-the-context-of-limited-supply, доступно 4 июня 2021 г.).
Sources
In the knowledge graph
- IRI
references/10665-354214.sec-004.13 - provenance: extracted
- read from
references/10665-354214.sec-004.13.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-354214/sections/sec-004-список-литературы.md
-
Chinn J, Sedighim S, Kirby KA, Hohmann S, Hameed AB, Jolley J et al. Characteristics and Outcomes of Women With COVID-19 Giving Birth at US Academic Centers During the COVID-19 Pandemic. JAMA Netw Open. 2021;4:e2120456. doi: 10.1001/jamanetworkopen.2021.20456.
· extracted · doi:10.1001/jamanetworkopen.2021.20456 · source:references/10665-354214.sec-004.14.jsonChinn J, Sedighim S, Kirby KA, Hohmann S, Hameed AB, Jolley J et al. Characteristics and Outcomes of Women With COVID-19 Giving Birth at US Academic Centers During the COVID-19 Pandemic. JAMA Netw Open. 2021;4:e2120456. doi: 10.1001/jamanetworkopen.2021.20456.
- Issued
- 2021
- Type
- article-journal
- DOI
- 10.1001/jamanetworkopen.2021.20456
- As printed
- Chinn J, Sedighim S, Kirby KA, Hohmann S, Hameed AB, Jolley J et al. Characteristics and Outcomes of Women With COVID-19 Giving Birth at US Academic Centers During the COVID-19 Pandemic. JAMA Netw Open. 2021;4:e2120456. doi: 10.1001/jamanetworkopen.2021.20456.
Sources
In the knowledge graph
- IRI
references/10665-354214.sec-004.14 - provenance: extracted
- read from
references/10665-354214.sec-004.14.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-354214/sections/sec-004-список-литературы.md
-
Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370:m3320. doi: 10.1136/bmj.m3320.
· extracted · doi:10.1136/bmj.m3320 · source:references/10665-354214.sec-004.15.jsonAllotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370:m3320. doi: 10.1136/bmj.m3320.
- Issued
- 2020
- Type
- article-journal
- DOI
- 10.1136/bmj.m3320
- As printed
- Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370:m3320. doi: 10.1136/bmj.m3320.
Sources
- doi:10.1136/bmj.m3320 (doi)
In the knowledge graph
- IRI
references/10665-354214.sec-004.15 - provenance: extracted
- read from
references/10665-354214.sec-004.15.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-354214/sections/sec-004-список-литературы.md
-
Qiao Y, Lopes de Abreu AdJ, Dias CZ, Meng X, Ferreira RV, Gonçalves Pereira R et al. Safety profile of COVID-19 vaccines in pregnant and postpartum women in brazil. medRxiv. 2021:2021.12.14.21267777. doi: 10.1101/2021.12.14.21267777.
· extracted · doi:10.1101/2021.12.14.21267777 · source:references/10665-354214.sec-004.16.jsonQiao Y, Lopes de Abreu AdJ, Dias CZ, Meng X, Ferreira RV, Gonçalves Pereira R et al. Safety profile of COVID-19 vaccines in pregnant and postpartum women in brazil. medRxiv. 2021:2021.12.14.21267777. doi: 10.1101/2021.12.14.21267777.
- Issued
- 2021
- Type
- document
- DOI
- 10.1101/2021.12.14.21267777
- As printed
- Qiao Y, Lopes de Abreu AdJ, Dias CZ, Meng X, Ferreira RV, Gonçalves Pereira R et al. Safety profile of COVID-19 vaccines in pregnant and postpartum women in brazil. medRxiv. 2021:2021.12.14.21267777. doi: 10.1101/2021.12.14.21267777.
Sources
In the knowledge graph
- IRI
references/10665-354214.sec-004.16 - provenance: extracted
- read from
references/10665-354214.sec-004.16.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-354214/sections/sec-004-список-литературы.md
-
Interim recommendations for an extended primary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised persons. Geneva: World Health Organization 2021 (https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-immunocompromised-persons, доступно 15 марта 2022 г.).
· extracted · link · source:references/10665-354214.sec-004.17.jsonInterim recommendations for an extended primary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised persons. Geneva: World Health Organization 2021 (https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-immunocompromised-persons, доступно 15 марта 2022 г.).
- Issued
- 2022
- Type
- document
- As printed
- Interim recommendations for an extended primary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised persons. Geneva: World Health Organization 2021 (https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-immunocompromised-persons, доступно 15 марта 2022 г.).
Sources
- www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-immunocompromised-persons (canonical)
In the knowledge graph
- IRI
references/10665-354214.sec-004.17 - provenance: extracted
- read from
references/10665-354214.sec-004.17.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-354214/sections/sec-004-список-литературы.md
-
Bates Timothy A, McBride Savannah K, Leier Hans C, Guzman G, Lyski Zoe L, Schoen D et al. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Science Immunology.0:eabn8014. doi: 10.1126/sciimmunol.abn8014.
· extracted · doi:10.1126/sciimmunol.abn8014 · source:references/10665-354214.sec-004.18.jsonBates Timothy A, McBride Savannah K, Leier Hans C, Guzman G, Lyski Zoe L, Schoen D et al. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Science Immunology.0:eabn8014. doi: 10.1126/sciimmunol.abn8014.
- Type
- document
- DOI
- 10.1126/sciimmunol.abn8014
- As printed
- Bates Timothy A, McBride Savannah K, Leier Hans C, Guzman G, Lyski Zoe L, Schoen D et al. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Science Immunology.0:eabn8014. doi: 10.1126/sciimmunol.abn8014.
Sources
In the knowledge graph
- IRI
references/10665-354214.sec-004.18 - provenance: extracted
- read from
references/10665-354214.sec-004.18.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-354214/sections/sec-004-список-литературы.md
-
WHO, UNICEF, UNESCO. Considerations for school-related public health measures in the context of COVID-19: annex to considerations in adjusting public health and social measures in the context of COVID-19, 14 September 2020. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/handle/10665/334294, доступно 15 марта 2022 г.). Предварительные рекомендации по применению инактивированной вакцины CoronaVac против COVID-19, разработанной Sinovac: временное руководство
· extracted · link · source:references/10665-354214.sec-004.19.jsonWHO, UNICEF, UNESCO. Considerations for school-related public health measures in the context of COVID-19: annex to considerations in adjusting public health and social measures in the context of COVID-19, 14 September 2020. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/handle/10665/334294, доступно 15 марта 2022 г.). Предварительные рекомендации по применению инактивированной вакцины CoronaVac против COVID-19, разработанной Sinovac: временное руководство
- Issued
- 2022
- Type
- document
- As printed
- WHO, UNICEF, UNESCO. Considerations for school-related public health measures in the context of COVID-19: annex to considerations in adjusting public health and social measures in the context of COVID-19, 14 September 2020. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/handle/10665/334294, доступно 15 марта 2022 г.). Предварительные рекомендации по применению инактивированной вакцины CoronaVac против COVID-19, разработанной Sinovac: временное руководство
Sources
- apps.who.int/iris/handle/10665/334294 (canonical)
In the knowledge graph
- IRI
references/10665-354214.sec-004.19 - provenance: extracted
- read from
references/10665-354214.sec-004.19.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-354214/sections/sec-004-список-литературы.md